Safety, Reactogenicity and Immunogenicity Study of ReCOV

NCT04818801 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Covid19

Interventions

BIOLOGICAL: Recombinant two-component COVID-19 vaccine (CHO cell)
OTHER: Placebo

Sponsor

Jiangsu Rec-Biotechnology Co., Ltd.

Collaborators

[object Object]